Advertisement

Infection

pp 1–9 | Cite as

Early versus late onset bloodstream infection during neutropenia after high-dose chemotherapy for hematologic malignancy

  • Andreas F. WidmerEmail author
  • Winfried V. Kern
  • Jan A. Roth
  • Markus Dettenkofer
  • Tim Goetting
  • Hartmut Bertz
  • Christian Theilacker
  • the Hospital Infection Surveillance System for Patients with Hematologic/Oncologic Malignancies Study Group (ONKO-KISS)
Original Paper

Abstract

Purpose

The length of neutropenia has a significant impact on the incidence of bloodstream infection (BSI) in cancer patients, but limited information is available about the pathogen distribution in late BSI.

Methods

Between 2002 and 2014, BSI episodes in patients with neutropenia receiving chemotherapy for hematologic malignancies were prospectively identified by multicenter, active surveillance in Germany, Switzerland and Austria. The incidence of first BSI episodes, their microbiology and time to BSI onset during the first episode of neutropenia of 15,988 patients are described.

Results

The incidence rate of BSI episodes was 14.7, 8.7, and 4.7 per 1000 patient-days in the first, second, and third week of neutropenia, respectively. BSI developed after a median of 5 days of neutropenia (interquartile range [IQR] 3–10 days). The medium duration of neutropenia to BSI onset was 4 days in Escherichia coli (IQR 3–7 days), Klebsiella spp. (2–8 days), and Staphylococcus aureus (3–6 days). In contrast, BSI due to Enterococcus faecium occurred after a median of 9 days (IQR 6–14 days; p < 0.001 vs. other BSI). Late onset of BSI (occurring after the first week of neutropenia) was also observed for Stenotrophomonas maltophilia (12 days, IQR 7–17 days; p < 0.001), and non-albicans Candida spp. (13 days, IQR 8–19 days; p < 0.001).

Conclusions

Over the course of neutropenia, the proportion of difficult to treat pathogens such as E. faecium, S. maltophilia, and Candida spp. increased. Among other factors, prior duration of neutropenia may help to guide empiric antimicrobial treatment in febrile neutropenia.

Keywords

Bacteremia Bloodstream infection Hematologic malignancy Neutropenia 

Notes

Acknowledgements

We would like to thank Dr. Maja Weisser and Dr. Nina Khanna for their help in infection documentation and data analysis. We also would like to thank Regina Babikir, Winfried Ebner for their support in managing the study and data collection. In addition, we would like to thank the medical staff and study nurses at all the participating centers for the invaluable support they provided to the studies over the years. This study has been presented in part at the 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam, the Netherlands.The study was supported in part with funds from the German Federal Ministry of Health.

Compliance with ethical standards

Conflict of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Supplementary material

15010_2019_1327_MOESM1_ESM.docx (55 kb)
Supplementary material 1 (DOCX 54 kb)

References

  1. 1.
    Mikulska M, Del Bono V, Raiola AM, Bruno B, Gualandi F, Occhini D, et al. Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of Gram-negative rods and increasing antibiotic resistance. Biol Blood Marrow Transpl. 2009;15:47–53.  https://doi.org/10.1016/j.bbmt.2008.10.024.CrossRefGoogle Scholar
  2. 2.
    Almyroudis NG, Fuller A, Jakubowski A, Sepkowitz K, Jaffe D, Small TN, et al. Pre- and post-engraftment bloodstream infection rates and associated mortality in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2005;7:11–7.  https://doi.org/10.1111/j.1399-3062.2005.00088.x.CrossRefGoogle Scholar
  3. 3.
    Marin M, Gudiol C, Ardanuy C, Garcia-Vidal C, Jimenez L, Domingo-Domenech E, et al. Factors influencing mortality in neutropenic patients with haematologic malignancies or solid tumours with bloodstream infection. Clin Microbiol Infect. 2015;21:583–90.  https://doi.org/10.1016/j.cmi.2015.01.029.CrossRefGoogle Scholar
  4. 4.
    Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis. 2003;36:1103–10.  https://doi.org/10.1086/374339.CrossRefGoogle Scholar
  5. 5.
    Mikulska M, Viscoli C, Orasch C, Livermore DM, Averbuch D, Cordonnier C, et al. Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients. J Infect. 2014;68:321–31.  https://doi.org/10.1016/j.jinf.2013.12.006.CrossRefGoogle Scholar
  6. 6.
    Averbuch D, Orasch C, Cordonnier C, Livermore DM, Mikulska M, Viscoli C, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica. 2013;98:1826–35.  https://doi.org/10.3324/haematol.2013.091025.CrossRefGoogle Scholar
  7. 7.
    Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:427–31.  https://doi.org/10.1093/cid/ciq147.CrossRefGoogle Scholar
  8. 8.
    Safdar A, Armstrong D. Infections in patients with hematologic neoplasms and hematopoietic stem cell transplantation: neutropenia, humoral, and splenic defects. Clin Infect Dis. 2011;53:798–806.  https://doi.org/10.1093/cid/cir492.CrossRefGoogle Scholar
  9. 9.
    Gustinetti G, Mikulska M. Bloodstream infections in neutropenic cancer patients: a practical update. Virulence. 2016;7:280–97.  https://doi.org/10.1080/21505594.2016.1156821.CrossRefGoogle Scholar
  10. 10.
    Taur Y, Xavier JB, Lipuma L, Ubeda C, Goldberg J, Gobourne A, et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2012;55:905–14.  https://doi.org/10.1093/cid/cis580.CrossRefGoogle Scholar
  11. 11.
    Safdar N, Kluger DM, Maki DG. A review of risk factors for catheter-related bloodstream infection caused by percutaneously inserted, noncuffed central venous catheters: implications for preventive strategies. Medicine (Baltimore). 2002;81:466–79.CrossRefGoogle Scholar
  12. 12.
    Rosa RG, Goldani LZ, dos Santos RP. Risk factors for multidrug-resistant bacteremia in hospitalized cancer patients with febrile neutropenia: a cohort study. Am J Infect Control. 2014;42:74–6.  https://doi.org/10.1016/j.ajic.2013.06.025.CrossRefGoogle Scholar
  13. 13.
    Dettenkofer M, Wenzler-Rottele S, Babikir R, Bertz H, Ebner W, Meyer E, et al. Surveillance of nosocomial sepsis and pneumonia in patients with a bone marrow or peripheral blood stem cell transplant: a multicenter project. Clin Infect Dis. 2005;40:926–31.  https://doi.org/10.1086/428046.CrossRefGoogle Scholar
  14. 14.
    Weisser M, Theilacker C, Tschudin Sutter S, Babikir R, Bertz H, Gotting T, et al. Secular trends of bloodstream infections during neutropenia in 15 181 haematopoietic stem cell transplants: 13-year results from a European multicentre surveillance study (ONKO-KISS). Clin Microbiol Infect. 2017;23:854–9.  https://doi.org/10.1016/j.cmi.2017.03.020.CrossRefGoogle Scholar
  15. 15.
    Kern WV, Weber S, Dettenkofer M, Kaier K, Bertz H, Behnke M, et al. Impact of fluoroquinolone prophylaxis during neutropenia on bloodstream infection: Data from a surveillance program in 8755 patients receiving high-dose chemotherapy for haematologic malignancies between 2009 and 2014. J Infect. 2018;77:68–74.  https://doi.org/10.1016/j.jinf.2018.05.004.CrossRefGoogle Scholar
  16. 16.
    Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36:309–32.  https://doi.org/10.1016/j.ajic.2008.03.002.CrossRefGoogle Scholar
  17. 17.
    Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control. 1988;16:128–40.CrossRefGoogle Scholar
  18. 18.
    European Centre for Disease Prevention and Control. Surveillance of antimicrobial resistance in Europe 2016. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2017. https://ecdc.europa.eu/en/publications-data/antimicrobial-resistance-surveillance-europe-2016. Accessed 26 May 2017.
  19. 19.
    Meyer E, Beyersmann J, Bertz H, Wenzler-Rottele S, Babikir R, Schumacher M, et al. Risk factor analysis of blood stream infection and pneumonia in neutropenic patients after peripheral blood stem-cell transplantation. Bone Marrow Transpl. 2007;39:173–8.  https://doi.org/10.1038/sj.bmt.1705561.CrossRefGoogle Scholar
  20. 20.
    Hieke S, Bertz H, Dettenkofer M, Schumacher M, Beyersmann J. Initially fewer bloodstream infections for allogeneic vs. autologous stem-cell transplants in neutropenic patients. Epidemiol Infect. 2013;41:158–64.  https://doi.org/10.1017/s0950268812000283.CrossRefGoogle Scholar
  21. 21.
    Herbers AH, de Haan AF, van der Velden WJ, Donnelly JP, Blijlevens NM. Mucositis not neutropenia determines bacteremia among hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2014;16:279–85.  https://doi.org/10.1111/tid.12195.CrossRefGoogle Scholar
  22. 22.
    Ubeda C, Taur Y, Jenq RR, Equinda MJ, Son T, Samstein M, et al. Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. J Clin Invest. 2010;120:4332–41.  https://doi.org/10.1172/JCI43918.CrossRefGoogle Scholar
  23. 23.
    Fan D, Coughlin LA, Neubauer MM, Kim J, Kim MS, Zhan X, et al. Activation of HIF-1alpha and LL-37 by commensal bacteria inhibits Candida albicans colonization. Nat Med. 2015;21:808–14.  https://doi.org/10.1038/nm.3871.CrossRefGoogle Scholar
  24. 24.
    Kamboj M, Chung D, Seo SK, Pamer EG, Sepkowitz KA, Jakubowski AA, et al. The changing epidemiology of vancomycin-resistant Enterococcus (VRE) bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Biol Blood Marrow Transpl. 2010;16:1576–81.  https://doi.org/10.1016/j.bbmt.2010.05.008.CrossRefGoogle Scholar
  25. 25.
    Satlin MJ, Soave R, Racanelli AC, Shore TB, van Besien K, Jenkins SG, et al. The emergence of vancomycin-resistant enterococcal bacteremia in hematopoietic stem cell transplant recipients. Leuk Lymphoma. 2014;55:2858–65.  https://doi.org/10.3109/10428194.2014.896007.CrossRefGoogle Scholar
  26. 26.
    Kang Y, Vicente M, Parsad S, Brielmeier B, Pisano J, Landon E, et al. Evaluation of risk factors for vancomycin-resistant Enterococcus bacteremia among previously colonized hematopoietic stem cell transplant patients. Transpl Infect Dis. 2013;15:466–73.  https://doi.org/10.1111/tid.12120.Google Scholar
  27. 27.
    Gudiol C, Ayats J, Camoez M, Dominguez MA, Garcia-Vidal C, Bodro M, et al. Increase in bloodstream infection due to vancomycin-susceptible Enterococcus faecium in cancer patients: risk factors, molecular epidemiology and outcomes. PLoS One. 2013;8:e74734.  https://doi.org/10.1371/journal.pone.0074734.CrossRefGoogle Scholar
  28. 28.
    Blennow O, Ljungman P, Sparrelid E, Mattsson J, Remberger M. Incidence, risk factors, and outcome of bloodstream infections during the pre-engraftment phase in 521 allogeneic hematopoietic stem cell transplantations. Transpl Infect Dis. 2014;16:106–14.  https://doi.org/10.1111/tid.12175.CrossRefGoogle Scholar
  29. 29.
    Yeshurun M, Gafter-Gvili A, Thaler M, Keller N, Nagler A, Shimoni A. Clinical characteristics of Stenotrophomonas maltophilia infection in hematopoietic stem cell transplantation recipients: a single center experience. Infection. 2010;38:211–5.  https://doi.org/10.1007/s15010-010-0023-2.CrossRefGoogle Scholar
  30. 30.
    Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis. 2000;181:309–16.  https://doi.org/10.1086/315193.CrossRefGoogle Scholar
  31. 31.
    Mann PA, McNicholas PM, Chau AS, Patel R, Mendrick C, Ullmann AJ, et al. Impact of antifungal prophylaxis on colonization and azole susceptibility of Candida species. Antimicrob Agents Chemother. 2009;53:5026–34.  https://doi.org/10.1128/AAC.01031-09.CrossRefGoogle Scholar
  32. 32.
    Gamaletsou MN, Walsh TJ, Zaoutis T, Pagoni M, Kotsopoulou M, Voulgarelis M, et al. A prospective, cohort, multicentre study of candidaemia in hospitalized adult patients with haematological malignancies. Clin Microbiol Infect. 2014;20:O50–7.  https://doi.org/10.1111/1469-0691.12312.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Andreas F. Widmer
    • 1
    Email author
  • Winfried V. Kern
    • 2
  • Jan A. Roth
    • 1
  • Markus Dettenkofer
    • 3
  • Tim Goetting
    • 3
  • Hartmut Bertz
    • 4
  • Christian Theilacker
    • 1
    • 2
  • the Hospital Infection Surveillance System for Patients with Hematologic/Oncologic Malignancies Study Group (ONKO-KISS)
  1. 1.Division of Infectious Diseases and Hospital Epidemiology, University Hospital BaselUniversity of BaselBaselSwitzerland
  2. 2.Division of Infectious Diseases, Department of Medicine II, University Hospital and Medical Center, Faculty of MedicineAlbert-Ludwigs-UniversityFreiburgGermany
  3. 3.Department of Environmental Health Sciences and Hospital Infection Control, University Hospital and Medical Center, Faculty of MedicineAlbert-Ludwigs-UniversityFreiburgGermany
  4. 4.Division of Hematology, Oncology, and Stem Cell Transplantation, Department of Medicine I, University Hospital and Medical Center, Faculty of MedicineAlbert-Ludwigs-UniversityFreiburgGermany

Personalised recommendations